Gross-to-Net 2021: Benchmark Survey Report

In the past year, COVID-19 has expedited efforts for pharmaceutical manufacturers to adopt improved and automated solutions to accurately manage their Gross-to-Net (GTN) forecasting and accrual processes. We polled 40 life sciences manufacturers from across the United States to gauge how they are adjusting to recent changes by asking about motivations, methods, and current blindspots involved in their GTN processes and methodologies. This report shares these responses, measuring industry trends and successful practices that can help manage GTN in 2021 and beyond.

Download now!